Even in poor-prognosis patients with plasmacytomas or high-risk cytogenetics, ORRs of 30.0% and 32.4%, respectively, were achieved with mezigdomide plus dexamethasone, while 50% of patients previously treated with anti-BCMA therapy responded to the doublet regimen, indicating substantial activity after multiple previous classes of therapy [33]. The gene discussed is TNFRSF17; the disease is plasmacytoma.